[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psychiatric-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psychiatric-diagnosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,78,109,152,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100598956","long-term-follow-up-of-depressive-disorders-in-psychiatric-care-100598956",false,"NCT07078227","Long-term Follow-up of Depressive Disorders in Psychiatric Care","5 Years Follow-up of the Study: \"Pharmacogenetics in Depressed Patients With Specific Focus on Difficult-to-treat Depresssion, Suicide Attempt and CYP2D6\"","Inclusion Criteria:\n\nParticipation in the study \"Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6\"\n\nExclusion Criteria:\n\nNot wanting to participate in the follow-up study","ALL","18 Years",{"count":19,"type":20},415,"ESTIMATED","OBSERVATIONAL","The project investigates long-term prognosis and predictors of treatment outcomes for difficult-to-treat depression in patients in secondary psychiatric care. The current patient cohort was collected in 2012-2021 in the study \"Pharmacogenetics in patients with depression with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6\". The cohort consists of 415 patients, examined carefully regarding diagnostic assessment and earlier treatment. All participants were also genotyped for the drug metabolizing enzymes CYP2D6 and CYP2C19. Blood samples were stored in biobank for other analyses linked to prognostic markers.\n\nThe patient cohort will now be followed up with a review of medical records and extraction of register data for a period of 5 years after their participation in the original study. The purpose of the study is to improve treatment and increase knowledge about long-term prognosis in difficult-to-treat depression. This is done by examining symptom profiles, monitoring clinical course and suicidality, and examining prognostic markers.",[24,25,26,27,28,29],"Depression","Psychiatric Diagnosis","Personality Disorders","Suicide, Attempted","CYP2D6 Polymorphism","Anhedonia","RECRUITING","2026-04-24",{"date":33,"type":34},"2026-04-30","ACTUAL",{"date":36,"type":34},"2025-06-01",{"date":38,"type":20},"2026-12-31",{"name":40,"class":41},"Region Skane","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100562864","the-key-to-integrated-trauma-treatment-in-psychosis-trial-100562864","NCT06608706","The Key to Integrated Trauma Treatment in Psychosis Trial","The Key to Integrated Trauma Treatment in Psychosis (Kit) Trial: A Pragmatic, Multicenter Effectiveness RCT of EMDR for Trauma Symptoms in Schizophrenia Spectrum Disorders","KIT","Inclusion Criteria:\n\n1. aged ≥ 16 years\n2. diagnosis of F20-29 in the ICD-10 assessed using SCID 5 CV\n3. reporting trauma \\> 1 month prior to assessment\n4. being currently distressed by the reported trauma(s), i.e., ≥ 5 (from 0 = not at all, to 10 = extremely) on item 21c on the Trauma and Life Events Checklist (TALE)\n5. able and motivated for engaging in trauma focused (TF) therapy\n6. able to understand and give informed consent; consent capacity for psychological treatment choices and consent to study procedures.\n\nExclusion Criteria:\n\n1. primary diagnosis of substance use\u002Falcohol dependence\n2. inability to understand spoken Norwegian\n3. organic psychosis or a neurological disorder\n4. acute state of psychosis defined as:\n\n   1. hospitalized in an acute ward the last 6 weeks or\n   2. major change in antipsychotic medication type or started\u002Fstopped antipsychotic medication last 6 weeks or\n   3. other mental health crises last 6 weeks\n5. current or previous (past 6 months) TF therapy","16 Years",{"count":53,"type":20},187,"INTERVENTIONAL",[56],"NA","Schizophrenia spectrum disorders (SSDs) have a significant trauma etiology: trauma has been reported in 65 - 80% in this patient group and have a negative impact on prognosis. Trauma treatment is currently not offered in SSDs due to a lack of evidence. KIT is a pragmatic trial comparing the effectiveness of added trauma focused therapy, Eye Movement Desensitization and Reprocessing (EMDR) to standard treatment in SSDs.\n\nThe study will compare EMDR as add on to treatment as usual (TAU) to TAU in patients with schizophrenia spectrum disorders (SSDs). The overall aim is to examine the effectiveness of EMDR on trauma symptoms in SSDs.\n\nParticipants will receive max. 26 sessions of EMDR, and complete assessments before, during and after the course of therapy, in addition to a period of time (6 months) after therapy to examine long-term effects.",[25,59,60],"Schizophrenia Disorders","Psychological Trauma, Historical",[62,63,64,65,66,67,68],"Psychosis","EMDR","Trauma treatment","Schizophrenia spectrum disorders","Childhood trauma","Psychological trauma","PTSD","2026-04-21",{"date":31,"type":34},{"date":72,"type":34},"2024-09-01",{"date":74,"type":20},"2028-12-31",{"name":76,"class":41},"Haukeland University Hospital",11,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100628943","digitizing-and-automating-the-diagnostic-psychiatric-assessment-process-100628943","NCT07468214","Digitizing and Automating the Diagnostic Psychiatric Assessment Process","DADAP","Inclusion criteria:\n\n\\- Families and children aged 6 to 17 with a mental health referral from primary care.\n\nExclusion criteria:\n\n* Minors under state care without stable attachment figures to report clinical history.\n* Presence of global developmental disorder or moderate to severe intellectual disability.\n* Incomplete, inaccurate, or unclear medical data.",true,"6 Years","17 Years",{"count":89,"type":20},35,"This is an observational study that will be responsible for the Spanish translation and cross-cultural adaptation, and validation of the Electronic Semi-Structured Psychiatric Interview for Children and Adolescents (EPSI-C), to examine, classify, prioritize, and diagnose patients.",[92,25],"Validation Studies",[94,95,96,97,98],"Cross-cultural adaptation","Child and adolescente psychiatry","mental health care assessment,","Translation","Validation","2026-03-11",{"date":101,"type":34},"2026-03-12",{"date":103,"type":34},"2026-01-09",{"date":105,"type":20},"2027-02-01",{"name":107,"class":41},"Irene Lopez Armenteros",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":85,"sex":117,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":54,"phases":121,"briefSummary":123,"conditions":124,"keywords":135,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":108},"100559957","phase-3-vitamin-d-in-pregnancy-for-prevention-of-early-childhood-asthma-100559957","NCT06570889","VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma","VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma (VICTORY)","VICTORY","* Pregnant Danish women before week 26 with blood levels of EPA+DHA above 4.7% of total fatty acids\n* No current vitamin D intake above the recommended 400 IU\u002Fday\n* No endocrine-, heart-, kidney- or auto-immune disorders\n* No disorders requiring treatment with blood thinning medication","FEMALE","45 Years",{"count":120,"type":20},2000,[122],"PHASE3","The overall aim of the study is to develop a nutritional preventive vitamin D supplementation strategy in pregnancy for early childhood asthma\u002Fpersistent wheeze during the first three years of life as we hypothesize that supplementation in higher doses than recommended could reduce the risk of disease development.",[125,126,127,128,129,130,131,132,133,134,25],"Asthma","Respiratory Tract Infections","Gastrointestinal Infection","Croup","Eczema","Allergy","Wheezing","Fractures, Bone","Development, Child","Cognition Disorders in Children",[136,125,137,129,130,138,139,140,141,142],"Childhood","Infections","Development","Psychiatry","Bone development","Cognition","Growth","2025-09-24",{"date":145,"type":34},"2025-09-30",{"date":147,"type":34},"2024-12-20",{"date":149,"type":20},"2033-03",{"name":151,"class":41},"Professor Klaus Bønnelykke",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":85,"sex":117,"minAge":17,"maxAge":118,"enrollmentInfo":160,"targetDuration":4,"studyType":54,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":168,"locationsCount":108},"100559140","phase-3-fish-oil-in-pregnancy-for-personalized-prevention-of-early-childhood-asthma-100559140","NCT06560255","Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma","Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma (FREYA)","FREYA","* Pregnant Danish women before week 26 with blood levels of EPA+DHA below 4.7% of total fatty acids\n* No planned use of fish oil supplementations\n* No endocrine-, heart-, kidney- or auto-immune disorders\n* No disorders requiring treatment with blood thinning medication",{"count":120,"type":20},[122],"The overall aim of the study is to develop a nutritional preventive fish oil supplementation strategy in pregnancy for early childhood asthma\u002Fpersistent wheeze during the first three years of life as we hypothesize that both supplementations in higher doses than recommended could reduce the risk of disease development.",[125,126,127,128,129,130,131,132,133,134,25],[136,125,137,129,130,138,139,140,141,142],{"date":145,"type":34},{"date":147,"type":34},{"date":149,"type":20},{"name":151,"class":41},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":117,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":54,"phases":179,"briefSummary":180,"conditions":181,"keywords":198,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":108},"100597441","therapeutic-writing-for-adults-suffering-from-chronic-pain-and-comorbid-mental-health-disorders-100597441","NCT07058532","Therapeutic Writing for Adults Suffering From Chronic Pain and Comorbid Mental Health Disorders","Therapeutic Writing Intervention in Pain Rehabilitation","TWfCP&MH","Inclusion Criteria:\n\n* Adult women (18 years or older), assigned female at birth and self-identify as women\n* Diagnosed with or experience of chronic, widespread (non-cancer) pain lasting at least two years\n* Diagnosed with or living with one or more mild mental health disorders (e.g., anxiety, mild depression), without current or past severe psychiatric conditions\n* Diagnosed with or experience of nociplastic pain (e.g., fibromyalgia)\n* Not currently using medications that may impair cognitive functioning (e.g., benzodiazepines, anticholinergics, opioids, antipsychotics)\n* Able to attend approximately 11 in-person visits over a 3-month period\n* Willing and able to participate in a structured therapeutic writing intervention\n* Purposefully selected to reflect a range of lived experiences relevant to the study's aims\n\nExclusion Criteria:\n\n* Presence of severe mental health disorders (e.g., schizophrenia, bipolar disorder, severe depression, or other psychotic conditions)\n* Use of medications known to impair memory, attention, or decision-making (e.g., benzodiazepines, anticholinergics, opioids, antipsychotics)\n* Participation in other concurrent treatments that may influence study outcomes\n* Cognitive limitations that would hinder meaningful engagement in the writing intervention\n* Individuals not assigned female at birth or who do not identify as women",{"count":178,"type":20},5,[56],"The goal of this observational study is to understand the effects and experiences of therapeutic writing interventions in adult women with chronic pain and co-occurring mental health conditions. The main questions it aims to answer are:\n\nCan therapeutic writing help relieve chronic pain and emotional distress?\n\nHow does writing support emotional processing, regulation, and meaning-making during rehabilitation?\n\nParticipants will take part in a two-part writing intervention involving:\n\nGuided writing exercises that focus on emotional processing, emotion regulation, and creating meaning.\n\nIndividual interviews after the writing sessions to explore their experiences.\n\nThe study uses qualitative analysis methods-phenomenology and logotherapy-to better understand how these writing interventions may support recovery, improve well-being, and offer non-pharmacological tools for managing chronic pain and mental health challenges.",[182,183,184,185,25,186,187,188,189,190,191,192,193,194,195,196,197],"Chronic Pain","Mental Health Disorder","Psychiatric &Amp;Amp;or Mood Disorder","Psychiatric Comorbidities","Emotional Pain","Emotional Distress","Emotion Regulation","Emotional Processing","Meaning of Life","Meaning Made","Meaning of Life and Life Satisfaction","Depressive Disorder","Anxiety Disorders","Sleep Disorder","Comorbid Depression","Process, Acceptance",[199,200,201,202,203,204,205,206,207,208,209,210,211,212],"Therapeutic writing","Chronic pain","Mental health disorders","Psychiatric disorders","Emotion regulation","Emotional processing","Meaning-making","Non-pharmacological intervention","Logotherapy","Phenomenological analysis","Psychosocial rehabilitation","Pain management","Pain coping","Creative writing","NOT_YET_RECRUITING","2025-06-30",{"date":216,"type":34},"2025-07-10",{"date":218,"type":20},"2025-08",{"date":220,"type":20},"2026-04",{"name":222,"class":41},"Toni Salikka"]